- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Iso-osmolar agent showshigher renal failure rate
Radiologists hoped the introduction of isoosmolarcontrast media would eliminatesevere adverse reactions to x-ray contrast.Alas, it was not to be.
Radiologists hoped the introduction of isoosmolar contrast media would eliminate severe adverse reactions to x-ray contrast. Alas, it was not to be. A large retrospective Swedish study identified a significantly higher rate of renal failure among patients administered iso-osmolar iodixanol (Visipaque) compared with patients who received low-osmolar ioxaglate (Hexabrix).
Dr. Per Liss and colleagues at the University of Uppsala presented their evaluation of 23,224 patients at the 2008 RSNA meeting. They found that 1.7% of patients who received iodixanol developed primary or secondary renal failure within 12 months of administration. The 12-month renal failure rate for patients who received ioxaglate was 0.8%.
Emerging PET/CT Agent Shows Promise in Detecting PCa Recurrence in Patients with Low PSA Levels
February 13th 202518F-DCFPyL facilitated detection of recurrent prostate cancer in 51 percent of patients with PSA levels ranging between 0.2 to 0.5 ng/ml, according to new research presented at the American Society of Clinical Oncology Genitourinary Cancers (ASCO-GU) Symposium.
